Stable Istotope Labelled Blinatumomab Biosimilar – Anti-CD19/CD3E mAb – Research Grade

Reference: PX-TA1067-SIL-1MG
Product nameStable Istotope Labelled Blinatumomab Biosimilar - Anti-CD19/CD3E mAb - Research Grade
SourceCAS 853426-35-4
SpeciesMus musculus
Expression systemMammalian cells
Molecular weight541kDa
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsAMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3
ReferencePX-TA1067-SIL
Related ProductsPX-P4004
NoteFor research use only. Not suitable for clinical or therapeutic use.
Isotype(scFv-kappa-heavy)-(scFv-heavy-kappa)
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-CD19/CD3E(Homo sapiens) (Blinatumomab) Monoclonal Antibody

Blinatumomab is a monoclonal antibody constructed by BiTE (bispecific T cell engagers), which is used to treat relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) with negative Philadelphia chromosome. Blinatumomab is available as a drug under the Blincyto™ brand.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Blinatumomab Biosimilar – Anti-CD19/CD3E mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below